her2-negative breast cancer Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Female only (1)
Any (1)

Phase 1 (2)

Interventional (2)

H3 Biomedicine Inc. (1)
Syros Pharmaceuticals (1)

No (2)

No (2)

Adult (18+) (2)

I am/have/had

I am/have/hadcancer

I am/have/hadHER2

I am/have/hadmeasurable disease

I am/have/hadbreast cancer

I am/have/hadestrogen

I am/have/hadher2- breast cancer

I am/have/hadstage iv breast cancer

I am/have/hadestrogen receptor

I am/have/hadepidermal growth factor receptor

I am/have/hadhair thinning

I am/have/hadscreening procedures

I am/have/hadgonadotropin

I am/have/hadmetastatic breast cancer

I am/have/haderbb1

I am/have/hadepidermal growth factor

I am/have/hadhuman chorionic gonadotropin

I am/have/hadsolid tumor

I am/have/hadher2-negative breast cancer

I am/have/hadsolid tumour

I am/have/hadalopecia

added new label for I am/have/had

more

I am looking for

I am looking forestrogen

I am looking forendocrine therapy

I am looking forhormone therapy

I am looking forfulvestrant

I am looking forpalbociclib

I am looking forgrowth factor

I am looking forgonadotropin

I am looking forhuman chorionic gonadotropin

I am looking forepidermal growth factor

added new label for I am looking for

more

Advanced Filters

Loading...

Found 2 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Multi-country trial
Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
For Females
Family Medicine
Recruiting

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …

erbb1

epidermal growth factor receptor

epidermal growth factor

growth factor

cancer

0 views
19 Feb, 2024

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Family Medicine
Recruiting

A Study of SY 5609 a Selective CDK7 Inhibitor in Advanced Solid Tumors

This is a dose escalation study and will be the first to administer SY-5609 alone to humans with select advanced solid tumors and in combination with Fulvestrant to patients with HR positive, HER2-negative breast cancer.

gonadotropin

metastatic breast cancer

HER2

breast cancer

solid tumour

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.